The Mechanism of Action of CDK4/6 Inhibitors

Conference Correspondent  - Breast Cancer, Video, SABCS
Matthew P. Goetz, MD
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Related Items
Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN
Videos published on July 28, 2020 in Interview with the Innovators, Video
Capecitabine Improves Outcomes in TNBC When Added to Other Systemic Therapy
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Breast Cancer
The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on July 14, 2020 in Interview with the Innovators, Video
The Role of Genetic Testing in Patients with Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on June 26, 2020 in Interview with the Innovators, Video
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, Drug Updates, FDA Updates
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Updates, In the News
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer, NCCN
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
Last modified: April 27, 2020